BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inducing Golgi complex fragmentation by inhibiting the transcription factor KLF7 or the Golgi integrity maintenance factors DLG3 or STX5 could treat pancreatic ductal adenocarcinoma (PDAC). In pancreas samples from...
BioCentury | Feb 7, 2019
Finance

Chinese Innovation: Threat or Opportunity?

Mounting techno-protectionism in response to China’s innovation drive seems destined to sap U.S. scientific leadership and entrepreneurial vigor, driving talent and capital to Europe and Asia. Biotech offers a compelling alternative to the current trend,...
BioCentury | Apr 13, 2018
Company News

Safety concerns for Acadia's Nuplazid resurface

On April 9, CNN called out a November 2017 safety report from the non-profit group Institute for Safe Medication Practices (ISMP), which identified 244 deaths among 2,236 adverse event reports filed for patients taking Nuplazid...
BioCentury | Apr 9, 2018
Company News

Acadia falls on Nuplazid safety concerns

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) fell $5.03 (23%) to $16.50 on Monday after CNN called out a November 2017 safety report from the non-profit group Institute for Safe Medication Practices (ISMP), which identified 244 deaths among...
BioCentury | Jan 12, 2018
Clinical News

Axovant reports Phase II data for dementia candidate nelotanserin

Axovant Sciences Ltd. (NASDAQ:AXON) reported data from 27 evaluable patients with dementia with Lewy bodies (DLB) and Parkinson's disease dementia who were experiencing frequent and recurrent visual hallucinations in a Phase II trial evaluating nelotanserin....
BioCentury | Nov 3, 2017
Regulation

Frame work

A little over four years into its implementation, FDA’s structured benefit-risk framework appears to be meeting its objectives of creating transparency into its approval decisions. The agency began to incorporate the framework templates into its...
BioCentury | Feb 17, 2017
Clinical News

Nelotanserin: Interim Ph II data

Interim data from 11 patients with Lewy body dementia or Parkinson's disease (PD) dementia who were experiencing frequent visual hallucinations in a double-blind, crossover, U.S. Phase II trial showed that once-daily oral nelotanserin met the...
BioCentury | Feb 17, 2017
Clinical News

ARX-04: Ph III SAP303 data

The open-label, U.S. Phase III SAP303 in 140 patients ages ≥40 who have undergone a surgical procedure with general or spinal anesthesia showed that 30 ug sublingual ARX-04 every hour as needed for pain management...
BioCentury | Feb 13, 2017
Clinical News

Axovant's nelotanserin heading to Phase III

Axovant Sciences Ltd. (NYSE:AXON) said it plans to begin a Phase III trial in 2H17 of nelotanserin based on interim data from 11 patients in a Phase II study to treat Lewy body dementia. The...
BioCentury | Jan 6, 2017
Clinical News

GAP3KO vaccine: Ph I data

...antibodies against P. falciparum and tested negative for blood-stage parasitemia. The deleted p52, p36 and sap1...
...Infectious Molecular target: NA Description: Live-attenuated Plasmodium falciparum vaccine with the p52 , p36 and sap1...
Items per page:
1 - 10 of 123